Hence, the selected CRC cell lines are a model for EGFR-targeted treatment by mAbs in vitro and - as seen in CRC patients - their RAS mutation status does not appear to be the single predictive marker for treatment response to EGFR-targeted mAb therapy. The gene discussed is EGFR; the disease is colorectal carcinoma.